Amneal launches generic Concerta
Amneal Pharmaceuticals has introduced its generic Concerta (methylphenidate hydrochloride extended-release) tablets. The drug is indicated to treat attention deficit/hyperactivity disorder as part of a total treatment program.
“We are extremely pleased to add our methylphenidate to the list of therapeutically equivalent generics for Concerta,” Jim Luce, executive vice president of sales and marketing at Brdigewater, N.J.-based Amneal, said. “The entrance of another AB-rated option adds to the choices provided to patients, prescribers and payers beyond non-substitutable BX-rated products and the brand.”
Amneal’s generic Concerta has begun shipping and is available in 18-, 27-, 36- and 54-mg dosage strengths, all of which are available in 90-count bottles, with 30-count bottles also available.
The product had a U.S. market size of $1.5 billion for the 12 months ended December 2017, according to IQVIA data.
“We are extremely pleased to add our methylphenidate to the list of therapeutically equivalent generics for Concerta,” Jim Luce, executive vice president of sales and marketing at Brdigewater, N.J.-based Amneal, said. “The entrance of another AB-rated option adds to the choices provided to patients, prescribers and payers beyond non-substitutable BX-rated products and the brand.”
Amneal’s generic Concerta has begun shipping and is available in 18-, 27-, 36- and 54-mg dosage strengths, all of which are available in 90-count bottles, with 30-count bottles also available.
The product had a U.S. market size of $1.5 billion for the 12 months ended December 2017, according to IQVIA data.